Cargando…

Pancreas Cancer‐Associated Weight Loss

Unintentional weight loss in patients with pancreatic cancer is highly prevalent and contributes to low therapeutic tolerance, reduced quality of life, and overall mortality. Weight loss in pancreatic cancer can be due to anorexia, malabsorption, and/or cachexia. Proper supportive care can stabilize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hendifar, Andrew E., Petzel, Maria Q.B., Zimmers, Teresa A., Denlinger, Crystal S., Matrisian, Lynn M., Picozzi, Vincent J., Rahib, Lola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2018
Materias:	Gastrointestinal Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516128/ https://www.ncbi.nlm.nih.gov/pubmed/30591550 http://dx.doi.org/10.1634/theoncologist.2018-0266

Ejemplares similares

Management of Patients With Pancreatic Cancer Using the “Right Track” Model
por: Rosenzweig, Allison, et al.
Publicado: (2023)

Pancreas Cancer‐Associated Pain Management
por: Coveler, Andrew L., et al.
Publicado: (2021)

Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss
por: Best, Till Dominik, et al.
Publicado: (2021)

18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation
por: David, John M., et al.
Publicado: (2019)

Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers
por: David, John M., et al.
Publicado: (2018)

Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD, RAINBOW, and RAINFALL Phase III Studies
por: Mansoor, Wasat, et al.
Publicado: (2021)

Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes
por: Jethwa, Krishan R., et al.
Publicado: (2018)

Leveraging patient‐reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience
por: Gupta, Arjun, et al.
Publicado: (2021)

KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas
por: Diehl, Adam C, et al.
Publicado: (2022)

FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
por: Klempner, Samuel J., et al.
Publicado: (2019)

Withholding the Introduction of Anti‐Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild‐Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)
por: Palmieri, Lola‐Jade, et al.
Publicado: (2019)

Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells showing intraductal growth and intratumoral hemorrhage: MRI features
por: Sato, Keisuke, et al.
Publicado: (2019)

Magnetic resonance cholangiopancreatography with compressed sensing at 1.5 T: clinical application for the evaluation of branch duct IPMN of the pancreas
por: Henninger, Benjamin, et al.
Publicado: (2020)

Estimated Projection of US Cancer Incidence and Death to 2040
por: Rahib, Lola, et al.
Publicado: (2021)

Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
por: Joseph, Cissimol P., et al.
Publicado: (2021)

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Al‐Batran, Salah‐Eddin, et al.
Publicado: (2020)

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy
por: George, Suzanne, et al.
Publicado: (2021)

Quantification of Pancreas Surface Lobularity on CT: A Feasibility Study in the Normal Pancreas
por: Sartoris, Riccardo, et al.
Publicado: (2021)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer
por: Lambregts, Doenja M. J., et al.
Publicado: (2011)

A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative
por: Pishvaian, Michael J., et al.
Publicado: (2016)

KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020)

Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP‐NETs: A Review of Key Issues
por: Anthony, Lowell B., et al.
Publicado: (2021)

Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
por: Perez, Kimberly, et al.
Publicado: (2023)

Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
por: Finn, Richard S, et al.
Publicado: (2022)

Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States
por: Abdel-Rahman, Omar, et al.
Publicado: (2018)

BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer
por: Tan, Elaine, et al.
Publicado: (2022)

Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs
por: Hao, Zhonglin, et al.
Publicado: (2022)

Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis
por: Klempner, Samuel J., et al.
Publicado: (2018)

Multi-omic molecular comparison of primary versus metastatic pancreatic tumours
por: Brar, Gagandeep, et al.
Publicado: (2019)

Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study
por: Mentrasti, Giulia, et al.
Publicado: (2022)

IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer
por: Moningi, Shalini, et al.
Publicado: (2019)

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial
por: Lipsyc-Sharf, Marla, et al.
Publicado: (2022)

Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis
por: Dodoo, Grace N, et al.
Publicado: (2023)

Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution
por: Holliday, Emma B, et al.
Publicado: (2022)

Reduced Field-of-View Diffusion-Weighted Magnetic Resonance Imaging of the Pancreas: Comparison with Conventional Single-Shot Echo-Planar Imaging
por: Kim, Hyungjin, et al.
Publicado: (2015)

Safety and Feasibility of Additional Tumor Debulking to First‐Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer
por: Gootjes, Elske C., et al.
Publicado: (2020)

Diffusion-weighted imaging complements T2-weighted MRI for tumour response assessment in squamous anal carcinoma
por: Prezzi, Davide, et al.
Publicado: (2023)

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
por: Fernández Montes, Ana, et al.
Publicado: (2023)

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF (V600E)-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
por: Tabernero, Josep, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lbngslmpsfpc39jtqm52nik54l